Journal of Pharmaceutical Investigation Reaches Q1 Standing With 5.5 Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug development research, has confirmed its standing in the major abstracting and indexing services that shape how scientific work is discovered, cited, and evaluated around the world. According to the journal’s published indexing record, the journal has been abstracted and indexed in the Science Citation Index Expanded, also known by its search designation SciSearch, since 2021, and it recorded an Impact Factor of 5.5 in 2022. Within its assigned subject category of Pharmacology and Pharmacy, that score placed the journal in the first quartile, ranking 48th out of 278 titles, a position that signals a meaningful level of influence within one of the most competitive categories in scientific publishing.

Abstracting and indexing is one of those quiet pieces of scientific infrastructure that most readers never think about, yet it determines nearly everything about how research travels. When a journal is indexed in a major database, every article it publishes is given a standardized bibliographic record, complete with authors, affiliations, keywords, and a persistent identifier, that can be retrieved by search engines, discovery platforms, and citation-tracking systems. Without that record, even excellent research risks becoming effectively invisible, buried in a journal that databases do not scan. Inclusion in the Science Citation Index Expanded, maintained as part of the Web of Science family of databases, is therefore a mark of editorial quality control and a practical guarantee that a journal’s output will be findable by the global research community.

The Science Citation Index Expanded has a long history as one of the core citation indexes in science. It covers thousands of journals across the natural sciences, engineering, medicine, and related disciplines, and its selection process is deliberately selective. Journals are evaluated on publishing standards, editorial rigor, international diversity of authorship and editorial boards, citation behavior, peer-review integrity, and the overall usefulness of the content to the research community. For a journal to be admitted, and then to remain, in the index requires sustained performance against those criteria. The Journal of Pharmaceutical Investigation’s entry into the index in 2021 marked the point at which its articles began accumulating formal citation records in the Web of Science ecosystem, the raw material from which metrics such as the Impact Factor are later computed.

That leads directly to the second and more widely discussed number: the 5.5 Impact Factor recorded for 2022. The Journal Impact Factor, produced annually in the Journal Citation Reports, is calculated by counting citations in a given year to items published in the journal during the two preceding years, then dividing by the number of citable items, typically articles and reviews, published in those same two years. A 2022 Impact Factor of 5.5 therefore reflects the average number of times that 2020 and 2021 articles in the journal were cited during 2022. It is a two-year citation window, which makes the metric sensitive to recent momentum and to fields where citation practices are fast-moving, as pharmaceutical research very much is.

Context matters enormously when interpreting that figure. A raw Impact Factor of 5.5 means little until it is compared against other journals in the same field, which is exactly what the category ranking provides. In Pharmacology and Pharmacy, a broad and heavily populated category with 278 indexed journals, the Journal of Pharmaceutical Investigation ranked 48th, placing it in the top quartile, or Q1. Quartile designations divide each category into four bands, and Q1 status is commonly used by libraries, funding agencies, and university evaluation committees as a shorthand for a journal sitting among the most influential quarter of titles in its discipline. For a journal that only entered the index in 2021, reaching Q1 within roughly two years of eligibility represents a notably rapid climb.

The mechanics behind that climb are worth understanding, because they illustrate how citation dynamics work in pharmaceutical research. Journals in this field benefit from several structural advantages: pharmaceutical science sits at the intersection of chemistry, biology, pharmacology, and clinical medicine, so articles tend to be cited from many neighboring disciplines rather than a single narrow community. Drug delivery technologies, formulation science, pharmacokinetics, and nanomedicine are all areas of intense global activity, and work published in these areas is frequently referenced in patents, review articles, and follow-up experimental studies. A journal that successfully attracts strong submissions in these active areas can accumulate citations quickly, and the two-year Impact Factor window rewards exactly that kind of momentum.

At the same time, the pharmaceutical research community has been vocal in recent years about the limits of single-number metrics, and any reading of the new figures should acknowledge those debates. The Impact Factor does not distinguish between a highly cited review and a routine research article, it can be influenced by a small number of exceptionally cited papers, and it says nothing about the methodological quality or reproducibility of individual studies. Initiatives such as the Declaration on Research Assessment, known as DORA, have urged institutions to move away from journal-level metrics when judging individual researchers, favoring article-level measures and qualitative expert review instead. The Journal of Pharmaceutical Investigation’s Q1 ranking is best understood as one signal among several, indicating broad visibility and citation uptake rather than certifying the quality of any specific paper.

For authors deciding where to submit, indexing status and quartile rankings still carry practical weight. Many national funding bodies and promotion committees maintain lists of acceptable journals built directly on Web of Science indexing and quartile positions, and some require publication in Q1 or Q2 titles for grant eligibility or degree completion. Indexing in the Science Citation Index Expanded also ensures that articles are preserved and discoverable through institutional libraries worldwide, which affects readership and, indirectly, future collaboration opportunities. In this sense, the journal’s documented indexing record and its 2022 metrics function as a form of infrastructure: they lower the friction between a published finding and the researcher who needs it.

What happens next will depend on the journal’s continued editorial performance. Impact Factors are recalculated every year, and quartile boundaries shift as competing journals rise and fall, so the 48th-of-278 position is a snapshot rather than a permanent achievement. Journals that sustain rigorous peer review, publish timely special issues in fast-moving areas such as biologics, drug delivery systems, and personalized pharmacotherapy, and maintain transparent editorial practices tend to hold their positions, while those that do not can slip quickly in a category as crowded as Pharmacology and Pharmacy. For now, the published record is clear: indexed in SciSearch since 2021, an Impact Factor of 5.5 in 2022, and a Q1 ranking within one of pharmacology’s largest and most competitive categories, a combination that firmly establishes the Journal of Pharmaceutical Investigation among the visible and influential outlets for pharmaceutical research.

Subject of Research: Indexing status and 2022 Impact Factor performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, Pharmacology and Pharmacy, Q1 ranking, Web of Science, citation metrics, scholarly publishing, journal ranking